- Conditions
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Interventions
- Alpha-1 MP
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 20 Years to 72 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
- Interventions
- Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- alpha-1 proteinase inhibitor (human)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Alpha-1 MP, alpha-1 proteinase inhibitor (human)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
- Conditions
- Pulmonary Emphysema in Alpha-1 PI Deficiency
- Interventions
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more